INBRIJA is a prescription medication specifically designed to address OFF episodes in adults with Parkinson’s disease who are already undergoing treatment with carbidopa/levodopa. It’s crucial to understand that INBRIJA is not a replacement for regular carbidopa/levodopa medication but rather a supplemental treatment for managing OFF periods. This article will explore important safety information and potential side effects associated with INBRIJA.
Important Safety Considerations for INBRIJA (Brija Money)
Before considering INBRIJA, it’s vital to discuss your medical history with your healthcare provider. This includes disclosing any pre-existing conditions such as asthma, chronic obstructive pulmonary disease (COPD), or other chronic lung diseases. Additionally, inform your doctor about any sleep-related issues, including daytime sleepiness, sleep disorders, or sudden sleep onset. Be sure to mention any medications you are currently taking, especially those known to increase sleepiness, such as antidepressants or antipsychotics.
Other conditions to discuss with your doctor before using INBRIJA include dizziness upon standing, nausea, excessive sweating, fainting, abnormal movements (dyskinesia), mental health concerns (hallucinations, psychosis), impulse control disorders (gambling, sexual urges, spending, binge eating), and glaucoma. Pregnant or breastfeeding women should also consult their healthcare providers as the effects of INBRIJA on pregnancy and nursing infants are unknown.
Certain medications may interact with INBRIJA. Inform your doctor if you are taking MAO-B inhibitors, dopamine (D2) antagonists (including phenothiazines, butyrophenones, risperidone, metoclopramide), isoniazid, iron salts, or multivitamins containing iron salts. Specifically, INBRIJA should not be used if you have taken a nonselective monoamine oxidase inhibitor (e.g., phenelzine, tranylcypromine) within the past two weeks.
Potential Side Effects of INBRIJA
INBRIJA, like any medication, can cause side effects. One of the most serious potential side effects is falling asleep suddenly during daily activities. This can occur even a year after starting treatment. If you experience drowsiness, avoid driving or engaging in tasks requiring alertness. This risk is heightened when taking other medications that induce sleepiness.
Other potential side effects include withdrawal-emergent hyperpyrexia and confusion (characterized by fever, muscle stiffness, and changes in breathing and heartbeat) if INBRIJA or carbidopa/levodopa is stopped abruptly. Low blood pressure upon standing (orthostatic hypotension), accompanied by dizziness, fainting, nausea, and sweating, can also occur. Get up slowly after sitting or lying down to minimize this risk.
INBRIJA may also cause or worsen hallucinations, psychosis, and unusual uncontrollable urges. Uncontrolled body movements (dyskinesia) may also be triggered or exacerbated. Bronchospasm, increased eye pressure (especially in individuals with glaucoma), and changes in liver test results are also possible. The most common side effects are cough, upper respiratory tract infection, nausea, and discoloration of saliva.
Dosage and Administration of INBRIJA
It is essential to follow your healthcare provider’s instructions regarding INBRIJA dosage. Do not exceed one dose (two capsules) per OFF period and a maximum of five doses (ten capsules) per day. Do not drive or operate machinery until you understand how INBRIJA affects you.
Conclusion: Consulting Your Healthcare Provider about Brija Money (INBRIJA)
This information is intended for general knowledge and does not constitute medical advice. Always consult your healthcare provider for personalized guidance regarding INBRIJA and its suitability for your specific situation. They can provide tailored recommendations based on your medical history, current medications, and individual needs. Open communication with your doctor is crucial for safely and effectively managing Parkinson’s disease.
